Literature DB >> 12529653

Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia.

J-M Luo1, H Yoshida, S Komura, N Ohishi, L Pan, K Shigeno, I Hanamura, K Miura, S Iida, R Ueda, T Naoe, Y Akao, R Ohno, K Ohnishi.   

Abstract

The SH2 domain-containing inositol 5'-phosphatase (SHIP) is crucial in hematopoietic development. To evaluate the possible tumor suppressor role of the SHIP gene in myeloid leukemogenesis, we examined primary leukemia cells from 30 acute myeloid leukemia (AML) patients, together with eight myeloid leukemia cell lines. A somatic mutation at codon 684, replacing Val with Glu, was detected in one patient, lying within the signature motif 2, which is the phosphatase active site. The results of an in vitro inositol 5'-phosphatase assay revealed that the mutation reduced catalytic activity of SHIP. Leukemia cells with the mutation showed enhanced Akt phosphorylation following IL-3 stimulation. K562 cells transfected with the mutated SHIP-V684E cDNA showed a growth advantage even at lower serum concentrations and resistance to apoptosis induced by serum deprivation and exposure to etoposide. These results suggest a possible role of the mutated SHIP gene in the development of acute leukemia and chemotherapy resistance through the deregulation of the phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3)/Akt signaling pathway. This is the first report of a mutation in the SHIP gene in any given human cancer, and indicates the need for more attention to be paid to this gene with respect to cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529653     DOI: 10.1038/sj.leu.2402725

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  Induced Dimerization Tools to Deplete Specific Phosphatidylinositol Phosphates.

Authors:  Jonathan Pacheco; Rachel C Wills; Gerald R V Hammond
Journal:  Methods Mol Biol       Date:  2021

3.  High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.

Authors:  Zhihong Zeng; Charlie Ly; Naval Daver; Jorge Cortes; Hagop M Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Ann Hematol       Date:  2021-03-31       Impact factor: 3.673

Review 4.  The prognostic and functional role of microRNAs in acute myeloid leukemia.

Authors:  Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

Review 5.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

6.  Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Authors:  J Khalife; H S Radomska; R Santhanam; X Huang; P Neviani; J Saultz; H Wang; Y-Z Wu; H Alachkar; M Anghelina; A Dorrance; J Curfman; C D Bloomfield; B C Medeiros; D Perrotti; L J Lee; R J Lee; M A Caligiuri; F Pichiorri; C M Croce; R Garzon; M L Guzman; J H Mendler; G Marcucci
Journal:  Leukemia       Date:  2015-05-14       Impact factor: 11.528

Review 7.  Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL.

Authors:  Michelle Pirruccello; Pietro De Camilli
Journal:  Trends Biochem Sci       Date:  2012-02-28       Impact factor: 13.807

8.  Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Authors:  Nicolas Chapuis; Jérôme Tamburini; Pascale Cornillet-Lefebvre; Lucile Gillot; Valérie Bardet; Lise Willems; Sophie Park; Alexa S Green; Norbert Ifrah; François Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

9.  Inositol phosphatase SHIP1 is a primary target of miR-155.

Authors:  Ryan M O'Connell; Aadel A Chaudhuri; Dinesh S Rao; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

10.  SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels.

Authors:  Sylvie Giuriato; Xavier Pesesse; Stéphane Bodin; Takehiko Sasaki; Cécile Viala; Evelyne Marion; Joseph Penninger; Stéphane Schurmans; Christophe Erneux; Bernard Payrastre
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.